Content area
Full text
PFIZER AND MYLAN, working through the Clinton Foundation, agreed to provide TB and HIV/AIDS drugs at a steep discount to patients in poor countries. Pfizer agreed to cut the price of its TB drug, rifabutin, by 60% for developing world patients. Mylan is making available its "second line in a box," a four-drug antiretroviral combo that comes in three pills for $425 annually. Appearing with Clinton to announce the deal were Pfizer's Jeff Kindler (left) and Mylan's Robert Coury (speaking), who said "Ensuring sustainable access to effective treatments in the developing world is a critical element in the global fight against HIV/AIDS." -Matthew Arnold